Literature DB >> 10155676

Costs of antifungal prophylaxis after bone marrow transplantation. A model comparing oral fluconazole, liposomal amphotericin and oral polyenes as prophylaxis against oropharyngeal infections.

A Stewart1, R Powles, M Hewetson, J Antrum, C Richardson, J Mehta.   

Abstract

We used a costs model to compare alternative modes of prophylaxis against oropharyngeal fungal infections in patients with leukaemia or myeloma who had undergone bone marrow transplantation (BMT). We compared 2 innovative pharmaceutical options (oral fluconazole and intravenous liposomal amphotericin) with existing standard practice (oral polyenes). Costs were measured over a 12-week treatment period, and were compared with the 2 effectiveness measures: (i) the avoidance of colonisation or infection; and (ii) the patients' ability to continue with prophylaxis in an uninfected state. The costs and effectiveness of BMT itself were not considered in this evaluation. The costs per successfully treated patient over a 12-week period were 28,956 pounds (1 pound = $US1.60, June 1995) for oral fluconazole, 53,225 pounds for liposomal amphotericin and 32,768 pounds for oral polyenes. Sensitivity analysis showed that the costs of liposomal amphotericin always exceeded those of the oral comparators, reflecting its high acquisition, preparation and administration costs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 10155676     DOI: 10.2165/00019053-199508040-00009

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  17 in total

Review 1.  Pharmacoeconomics of intravenous drug administration.

Authors:  S E Parker; P G Davey
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

Review 2.  Current status of bone marrow transplantation.

Authors:  K M Sullivan
Journal:  Transplant Proc       Date:  1989-06       Impact factor: 1.066

3.  Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients.

Authors:  J Tollemar; O Ringdén; S Andersson; B Sundberg; P Ljungman; E Sparrelid; G Tydén
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

4.  Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia.

Authors:  H G Welch; E B Larson
Journal:  N Engl J Med       Date:  1989-09-21       Impact factor: 91.245

Review 5.  Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: what is the state of the art? Ad HOC Working Group.

Authors:  D W Denning; J P Donnelly; K P Hellreigel; J Ito; P Martino; J W van't Wout
Journal:  Chemotherapy       Date:  1992       Impact factor: 2.544

6.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.

Authors:  J L Goodman; D J Winston; R A Greenfield; P H Chandrasekar; B Fox; H Kaizer; R K Shadduck; T C Shea; P Stiff; D J Friedman
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

Review 7.  Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of fungal infections.

Authors:  F Meunier-Carpentier
Journal:  Am J Med       Date:  1984-04       Impact factor: 4.965

Review 8.  Antifungal prophylaxis in immunocompromised hosts.

Authors:  S Reents; S D Goodwin; V Singh
Journal:  Ann Pharmacother       Date:  1993-01       Impact factor: 3.154

9.  Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Increased susceptibility to fungal infections.

Authors:  J D Pirsch; D G Maki
Journal:  Ann Intern Med       Date:  1986-05       Impact factor: 25.391

10.  Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome)--a report on 40 cases from a single centre.

Authors:  R Chopra; A Fielding; A H Goldstone
Journal:  Leuk Lymphoma       Date:  1992
View more
  8 in total

Review 1.  The cost of treating systemic fungal infections.

Authors:  R van Gool
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

3.  Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea.

Authors:  K Moeremans; L Annemans; Ji-So Ryu; Kang-Won Choe; Wan-Shik Shine
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

Review 4.  Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.

Authors:  A J Coukell; R N Brogden
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

Review 5.  Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence.

Authors:  Petros Pechlivanoglou; Robin De Vries; Simon M G J Daenen; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

6.  Economic aspects of treatment for fungal infections in cancer patients.

Authors:  K Torfs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

7.  Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis.

Authors:  Daoud Al-Badriyeh; Chin Fen Neoh; Kay Stewart; David C M Kong
Journal:  Clin Ophthalmol       Date:  2010-05-06

8.  Effect of formulation factors on in vitro transcorneal permeation of voriconazole from aqueous drops.

Authors:  Biswaranjan Mohanty; Sagar Kumar Mishra; Dipak K Majumdar
Journal:  J Adv Pharm Technol Res       Date:  2013-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.